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Background: Culprit lesions of patients with ST-elevation MI (STEMI) are characterized by plaque rupture and thrombus formation, features 
which have been associated with delayed arterial healing as compared to stable lesions in response to durable polymer drug-eluting stents (DES) 
implantation as compared to stable lesions. Biodegradable polymer DES aim to avoid this shortcoming by improving biocompatibility, and may 
potentially improve long-term clinical outcomes in STEMI patients.
Methods: We pooled individual patient data from two large-scale multicenter randomized clinical trials (ISAR-TEST 4 and LEADERS) comparing 
biodegradable polymer DES with durable polymer sirolimus-eluting stents (SES) and assessed clinical outcomes during follow-up through 4 years. 
The prespecified primary endpoint was major cardiac adverse events (MACE), defined as the composite of cardiac death, myocardial infarction, and 
target-lesion revascularization.
Results: No heterogeneity across the trials was observed in analyses of the primary and secondary endpoints. At four years, we observed a trend 
towards a lower risk of MACE for patients treated with biodegradable polymer DES versus durable polymer SES (HR 0.54, 95% CI 0.29-1.01, 
P=0.055). This was mainly driven by a significant reduction in the risk of target-lesion revascularization (HR 0.51, 95% CI 0.23-0.94, P=0.03), 
whereas no significant difference was observed for cardiac death (HR 0.56, 95% CI 0.17-1.86, P=0.34) and myocardial infarction (HR 0.62, 95% CI 
0.20-1.95, P=0.42) with biodegradable polymer DES as compared to durable polymer SES at four years. The risk of definite stent thrombosis showed 
no significant difference with biodegradable polymer DES as compared to durable polymer SES (HR 0.54, 95% CI 0.20-1.46, P=0.22).
Conclusions: These findings suggest that biodegradable polymer DES may improve clinical outcomes compared with durable polymer SES in 
patients with STEMI during long-term follow-up to 4 years.
